Search

Displaying results 2841 - 2850 of 8412 in total
  1. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Ag-lacosamide
  3. Drug

    Molybdenum

    go.drugbank.com/drugs/DB11137
    ApprovedInvestigational

    It is an essential trace dietary element and acts as a critical cofactor in several molybdenum-dependent enzymes that are involved in important cellular reactions and pathways, including xanthine oxidoreductase

    Mixtures: Liquid Opti-minplex +d, Iron 25mg With Vit B-cmplx, Vit C, Cu & Mo
  4. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inducers
  5. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244584] Etrolizumab is a humanized IgG1κ monoclonal antibody directed against the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins that, due to its target specificity, appears as or more

  6. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing acti...

    Synonyms: (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate, methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  7. Drug

    Hydroxocobalamin

    go.drugbank.com/drugs/DB00200
    ApprovedInvestigational

    Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency.

    Mixtures: Escavite DProducts: VITAMIN B12 DEP PAN 1000UG
  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]

  9. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [

  10. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. … PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates